Work

Real‐World Evidence Assessment of the Risk of Nonfatal Stroke in Patients Prescribed SGLT2 Inhibitors

Year: 2026

Type: article

Abstract: Aims Use of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in adults with Type 2 diabetes (AwT2D) has recently been associated with decreased stroke risk. In this study, we investigate the impact of SGLT2i on stroke. Materials and Methods We conducted a cohort study using an electronic health record (EHR) representing 66 million patients to examine whether AwT2D have a lower incidence of stroke and/or transient ischemic attack (TIA) if treated with SGLT2i. All analyses were completed utilizing high‐dimensional propensity score matching to control for confounders. Results AwT2D treated with SGLT2i compared to other antidiabetic medications, assessed after 1 year, starting 2 weeks after the date of prescription of SGLT2i or other antidiabetic drug, had a significantly lower incidence of any stroke (Odds Ratio (OR): 0.84 with 95% Confidence Interval (CI) 0.79–0.91, p < 0.001), hemorrhagic stroke (OR: 0.72 with 95% CI 0.59–0.88, p < 0.001), ischemic stroke (OR: 0.86 with 95% CI 0.77–0.95, p = 0.005), and TIA (OR: 0.87 with 95% CI 0.80–0.95, p = 0.003). Conclusion Among AwT2D, those treated with SGLT2i had lower incidence of stroke and TIA compared with adults treated with other antidiabetic medications.

Source: Stroke Research and Treatment

DOI: 10.1155/srat/6411721